PT  - JOURNAL ARTICLE
AU  - Gunadi,
AU  - Hakim, Mohamad Saifudin
AU  - Wibawa, Hendra
AU  - Marcellus,
AU  - Setiawaty, Vivi
AU  - Slamet,
AU  - Trisnawati, Ika
AU  - Supriyati, Endah
AU  - Khair, Riat El
AU  - Iskandar, Kristy
AU  - Afiahayati,
AU  - Siswanto,
AU  - Irene,
AU  - Anggorowati, Nungki
AU  - Daniwijaya, Edwin Widyanto
AU  - Agung Nugrahaningsih, Dwi Aris
AU  - Puspadewi, Yunika
AU  - Puspitarani, Dyah Ayu
AU  - Tania, Irene
AU  - Vujira, Khanza Adzkia
AU  - Ardlyamustaqim, Muhammad Buston
AU  - Gabriela, Gita Christy
AU  - Eryvinka, Laudria Stella
AU  - Nirmala, Bunga Citta
AU  - Geometri, Esensi Tarian
AU  - Darutama, Abirafdi Amajida
AU  - Kuswandani, Anisa Adityarini
AU  - Lestari,
AU  - Irianingsih, Sri Handayani
AU  - Khoiriyah, Siti
AU  - Lestari, Ina
AU  - Ananda, Nur Rahmi
AU  - Arguni, Eggi
AU  - Nuryastuti, Titik
AU  - Wibawa, Tri
AU  - ,
TI  - Is the infection of the SARS-CoV-2 Delta variant associated with the outcomes of COVID-19 patients?
AID  - 10.1101/2021.10.05.21262783
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.05.21262783
4099  - http://medrxiv.org/content/early/2021/10/07/2021.10.05.21262783.short
4100  - http://medrxiv.org/content/early/2021/10/07/2021.10.05.21262783.full
AB  - Background SARS-CoV-2 Delta variant (B.1.617.2) has been responsible for the current increase in COVID-19 infectivity rate worldwide. We compared the impact of the Delta variant and non-Delta variant on the COVID-19 outcomes in patients from Yogyakarta and Central Java provinces, Indonesia.Methods We ascertained 161 patients, 69 with the Delta variant and 92 with the non-Delta variant. The Illumina MiSeq next-generation sequencer was used to perform the whole genome sequences of SARS-CoV-2.Results The mean age of patients with Delta and the non-Delta variant was 27.3 ± 20.0 and 43.0 ± 20.9 (p=3×10−6). The patients with Delta variant consisted of 23 males and 46 females, while the patients with the non-Delta variant involved 56 males and 36 females (p=0.001). The Ct value of the Delta variant (18.4 ± 2.9) was significantly lower than the non-Delta variant (19.5 ± 3.8) (p=0.043). There was no significant difference in the hospitalization and mortality of patients with Delta and non-Delta variants (p=0.80 and 0.29, respectively). None of the prognostic factors was associated with the hospitalization, except diabetes with an OR of 3.6 (95% CI=1.02-12.5; p=0.036). Moreover, the patients with the following factors have been associated with higher mortality rate than patients without the factors: age ≥65 years, obesity, diabetes, hypertension, and cardiovascular disease with the OR of 11 (95% CI=3.4-36; p=8×10−5), 27 (95% CI=6.1-118; p=1×10−5), 15.6 (95% CI=5.3-46; p=6×10−7), 12 (95% CI=4-35.3; p=1.2×10−5), and 6.8 (95% CI=2.1-22.1; p=0.003), respectively. Multivariate analysis showed that age ≥65 years, obesity, diabetes, and hypertension were the strong prognostic factors for the mortality of COVID-19 patients with the OR of 3.6 (95% CI=0.58-21.9; p=0.028), 16.6 (95% CI=2.5-107.1; p=0.003), 5.5 (95% CI=1.3-23.7; p=0.021), and 5.8 (95% CI=1.02-32.8; p=0.047), respectively.Conclusions We show that the patients infected by the SARS-CoV-2 Delta variant have a lower Ct value than the patients infected by the non-Delta variant, implying that the Delta variant has a higher viral load, which might cause a more transmissible virus among humans. However, the Delta variant does not affect the COVID-19 outcomes in our patients. Our study also confirms the older age and comorbidity increase the mortality rate of COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Ministry of Education, Culture, Research and Technology, Indonesia, funded our study. The funders had no role in study design, data collection, and analysis, decision to publish, or manuscript preparation. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital approved our study (KE/FK/0563/EC/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in the submission. The sequence and metadata are shared through GISAID (www.gisaid.org).CIconfidence intervalORodds ratioVOCvariant of concern